GrippeEspagneV1, Main, Exploration, bibRecord, 000178

Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.

Identifieur interne : 000178 ( Main/Exploration ); précédent : 000177; suivant : 000179

Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.

Auteurs : Silvia Jiménez-Jorge [Espagne] ; Francisco Pozo [Espagne] ; Amparo Larrauri [Espagne]

Source :

Vaccine [ 1873-2518 ] ; 2015.

RBID : pubmed:25869892

Descripteurs français

KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Nouveau-né (MeSH), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Surveillance sentinelle (MeSH), Vaccination (méthodes), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Études cas-témoins (MeSH).
MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Vaccins antigrippaux.
- méthodes : Vaccination.
- prévention et contrôle : Grippe humaine.
- épidémiologie : Espagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Nourrisson, Nouveau-né, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Surveillance sentinelle, Études cas-témoins.
Wicri :
- geographic : Espagne.

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Humans (MeSH), Infant (MeSH), Infant, Newborn (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Sentinel Surveillance (MeSH), Spain (epidemiology), Treatment Outcome (MeSH), Vaccination (methods), Young Adult (MeSH).
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : Spain.
- epidemiology : Influenza, Human.
- methods : Vaccination.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Sentinel Surveillance, Treatment Outcome, Young Adult.

Abstract

INTRODUCTION

The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain.

METHODS

We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination.

RESULTS

In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%).

CONCLUSION

In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.

DOI: 10.1016/j.vaccine.2015.03.051
PubMed: 25869892

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 00174
to stream Main, to step Curation: 000174

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.</title>
<author><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name>
<affiliation wicri:level="3"><nlm:affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: silviajimenezjorge@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid, Spain. Electronic address: pacopozo@isciii.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name>
<affiliation wicri:level="3"><nlm:affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: alarrauri@isciii.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25869892</idno>
<idno type="pmid">25869892</idno>
<idno type="doi">10.1016/j.vaccine.2015.03.051</idno>
<idno type="wicri:Area/Main/Corpus">00174</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00174</idno>
<idno type="wicri:Area/Main/Curation">000174</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000174</idno>
<idno type="wicri:Area/Main/Exploration">000174</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.</title>
<author><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name>
<affiliation wicri:level="3"><nlm:affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: silviajimenezjorge@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid, Spain. Electronic address: pacopozo@isciii.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name>
<affiliation wicri:level="3"><nlm:affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: alarrauri@isciii.es.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Infant (MeSH)</term>
<term>Infant, Newborn (MeSH)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Sentinel Surveillance (MeSH)</term>
<term>Spain (epidemiology)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Vaccination (methods)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Espagne (épidémiologie)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Nourrisson (MeSH)</term>
<term>Nouveau-né (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Surveillance sentinelle (MeSH)</term>
<term>Vaccination (méthodes)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Études cas-témoins (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Case-Control Studies</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Sentinel Surveillance</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Surveillance sentinelle</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b>
</p>
<p>The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25869892</PMID>
<DateCompleted><Year>2016</Year>
<Month>03</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>06</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>33</Volume>
<Issue>29</Issue>
<PubDate><Year>2015</Year>
<Month>Jun</Month>
<Day>26</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.</ArticleTitle>
<Pagination><MedlinePgn>3276-80</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2015.03.051</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0264-410X(15)00359-X</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The agreement between interim and final influenza vaccine effectiveness (VE) estimates would support the use of interim assessments as a proxy for final VE results to guide health authorities in influenza prevention. We aimed to compare interim/final VE estimates in Spain.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We used a test-negative case-control study (cycEVA) for 2010/11-2013/14 seasons. Sensitivity analyses were carried out by type/subtype of influenza virus and by target groups for vaccination.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In general, interim estimates were higher compared to end-season estimates. Interim and final VE differences were higher for the target groups compared to all population. Subtype-specific interim/final VE estimates showed greater concordance (3-13%) than for any virus (7-24%).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In Spain, interim influenza VE estimates over 2010-2014 were a good proxy of the final protection of the vaccine. Interim and final estimates showed greater concordance for all population and if performed subtype-specific.</AbstractText>
<CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiménez-Jorge</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: silviajimenezjorge@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pozo</LastName>
<ForeName>Francisco</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Institute of Health Carlos III, National Centre for Microbiology, National Influenza Centre, 28220 Majadahonda, Madrid, Spain. Electronic address: pacopozo@isciii.es.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Larrauri</LastName>
<ForeName>Amparo</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>National Centre of Epidemiology, Institute of Health Carlos III, c/Monforte de Lemos no.5, 28029 Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain. Electronic address: alarrauri@isciii.es.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>cycEVA Study Team</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>04</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Case-control studies</Keyword>
<Keyword MajorTopicYN="N">Influenza</Keyword>
<Keyword MajorTopicYN="N">Interim analysis</Keyword>
<Keyword MajorTopicYN="N">Sentinel networks</Keyword>
<Keyword MajorTopicYN="N">Vaccine effectiveness</Keyword>
</KeywordList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>de Mateo</LastName>
<ForeName>Salvador</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Delgado-Sanz</LastName>
<ForeName>Concepción</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Casas</LastName>
<ForeName>Inmaculada</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>García-Cenoz</LastName>
<ForeName>Manuel</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Castilla</LastName>
<ForeName>Jesús</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rodríguez</LastName>
<ForeName>Carolina</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vega</LastName>
<ForeName>Tomás</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Quiñones</LastName>
<ForeName>Carmen</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Martínez</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vanrell</LastName>
<ForeName>Juana M</ForeName>
<Initials>JM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Giménez</LastName>
<ForeName>Jaume</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Castrillejo</LastName>
<ForeName>Daniel</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Altzíbar</LastName>
<ForeName>Jone M</ForeName>
<Initials>JM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>González-Carril</LastName>
<ForeName>Fernando</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ramos</LastName>
<ForeName>Julián M</ForeName>
<Initials>JM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Serrano</LastName>
<ForeName>María C</ForeName>
<Initials>MC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Martínez</LastName>
<ForeName>Ana</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Torner</LastName>
<ForeName>Nuria</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pérez</LastName>
<ForeName>Esteban</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gallardo</LastName>
<ForeName>Virtudes</ForeName>
<Initials>V</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>12</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>03</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>03</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>3</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25869892</ArticleId>
<ArticleId IdType="pii">S0264-410X(15)00359-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2015.03.051</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Communauté de Madrid</li>
</region>
<settlement><li>Madrid</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Jimenez Jorge, Silvia" sort="Jimenez Jorge, Silvia" uniqKey="Jimenez Jorge S" first="Silvia" last="Jiménez-Jorge">Silvia Jiménez-Jorge</name>
</region>
<name sortKey="Larrauri, Amparo" sort="Larrauri, Amparo" uniqKey="Larrauri A" first="Amparo" last="Larrauri">Amparo Larrauri</name>
<name sortKey="Pozo, Francisco" sort="Pozo, Francisco" uniqKey="Pozo F" first="Francisco" last="Pozo">Francisco Pozo</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000178 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000178 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeEspagneV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25869892
   |texte=   Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25869892" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeEspagneV1

This area was generated with Dilib version V0.6.37.
Data generation: Fri Sep 25 11:01:38 2020. Site generation: Sat Feb 13 17:38:04 2021

	Serveur d'exploration sur la grippe en Espagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Espagne

Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.

Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki